Montalto G, Lusher M, De Caro A, Multigner L, Sarles H, Delaage M
C R Acad Sci III. 1985;300(6):199-202.
A CaCO3-crystal growth inhibitor has recently been isolated from the calculi of patients affected by pancreatic lithiasis. It is a phosphoglycoprotein, with a molecular weight of 14,000, whose probable physiological role is the stabilization of exocrine pancreatic secretion which is supersaturated with respect to CaCO3. In order to isolate this inhibitor from human pancreatic juice, monoclonal antibodies to the protein were prepared and an immunoadsorbent column was developed. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis of proteins fixed by the immunoadsorbent reveals the form having a molecular weight of 14,000, in addition to other protein bands which have higher molecular weights (16,000, 16,800, 18,000, and 18,800). All of these different proteins are also recognized by a monospecific polyclonal antibody to the 14,000 molecular weight form. Using the same monospecific polyclonal antibody only one messenger RNA coding for this inhibitor has been demonstrated. Thus, this heterogeneity might be explained by post-translational modifications.
最近从患有胰腺结石的患者结石中分离出一种碳酸钙晶体生长抑制剂。它是一种磷糖蛋白,分子量为14,000,其可能的生理作用是稳定相对于碳酸钙呈过饱和状态的胰腺外分泌。为了从人胰液中分离这种抑制剂,制备了针对该蛋白的单克隆抗体并开发了免疫吸附柱。免疫吸附固定的蛋白质的十二烷基硫酸钠-聚丙烯酰胺凝胶电泳显示,除了分子量较高的其他蛋白条带(16,000、16,800、18,000和18,800)外,还有分子量为14,000的形式。所有这些不同的蛋白质也被针对分子量为14,000形式的单特异性多克隆抗体识别。使用相同的单特异性多克隆抗体,仅证明了一种编码该抑制剂的信使核糖核酸。因此,这种异质性可能是由翻译后修饰来解释的。